Department of Chemistry, Virginia Commonwealth University, 1001 W. Main Street, Richmond, Virginia 23284, United States.
Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, BioTech One, 800 East Leigh Street, Richmond, Virginia 23219, United States.
ACS Appl Bio Mater. 2021 Oct 18;4(10):7653-7662. doi: 10.1021/acsabm.1c00887. Epub 2021 Sep 27.
Controlled release of drugs from medical implants is an effective approach to reducing foreign body reactions and infections. We report here on a one-step 3D printing strategy to create drug-eluting polymer devices with a drug-loaded bulk and a drug-free coating. The spontaneously formed drug-free coating dramatically reduces the surface roughness of the implantable devices and serves as a protective layer to suppress the burst release of drugs. A high viscosity liquid silicone that can be extruded based on its shear-thinning property and quickly vulcanize upon exposure to ambient moisture is used as the ink for 3D printing. -Nitrosothiol type nitric oxide (NO) donors in their crystalline forms are selected as model drugs because of the potent antimicrobial, antithrombotic, and anti-inflammatory properties of NO. Direct ink writing of the homogenized polymer-drug mixtures generates rough and ill-defined device surfaces because of the exposed -nitrosothiol microparticles. When a low-viscosity silicone (polydimethylsiloxane) is added into the ink, this silicone diffuses outward upon deposition to form a drug-free outermost layer without compromising the integrity of the printed structures. -Nitrosoglutathione (GSNO) or -nitroso--acetylpenicillamine (SNAP) embedded in the printed silicone matrix releases NO under physiological conditions from days to about one month. The microsized drug crystals are well-preserved in the ink preparation and printing processes, which is one reason for the sustained NO release. Biofilm and cytotoxicity experiments confirmed the antibacterial property and safety of the printed NO-releasing devices. This additive manufacturing platform does not require dissolution of drugs and involves no thermal or UV processes and, therefore, offers unique opportunities to produce drug-eluting silicone devices in a customized manner.
药物的控释是减少异物反应和感染的有效方法。我们在此报告了一种一步 3D 打印策略,用于制造载药聚合物器件,其具有载药的本体和无药的涂层。自发形成的无药涂层显著降低了可植入器件的表面粗糙度,并作为保护层抑制药物的突释。基于其剪切变稀特性可挤出且暴露于环境湿度时可快速硫化的高粘度液体硅酮用作 3D 打印的墨水。由于一氧化氮 (NO) 的强大的抗菌、抗血栓和抗炎特性,选择以硝普盐型一氧化氮供体(-nitrosothiol type nitric oxide donors)作为模型药物。由于暴露的 - 硝基亚硝戊二酰硫醇(-nitrosothiol)微颗粒,均匀的聚合物-药物混合物的直接喷墨打印会产生粗糙且不明确的器件表面。当将低粘度硅酮(聚二甲基硅氧烷)添加到墨水中时,该硅酮在沉积时会向外扩散,形成无药的最外层,而不会影响打印结构的完整性。嵌入打印硅酮基质中的 - 谷胱甘肽硝化物(GSNO)或 - 亚硝基 - 乙酰青霉胺(SNAP)在生理条件下从数天到约一个月释放 NO。微尺寸的药物晶体在墨水制备和打印过程中得到了很好的保存,这是持续释放 NO 的原因之一。生物膜和细胞毒性实验证实了打印的释放 NO 的设备具有抗菌性能和安全性。这种增材制造平台不需要药物溶解,也不涉及热或 UV 工艺,因此为定制生产载药硅酮器件提供了独特的机会。